Author:
F. Cardona Andrés,Rolfo Christian,Malapelle Umberto,Miguel-Pérez Diego de
Abstract
The use of liquid biopsy (LB) has become highly relevant in the clinical field, and the acquisition of circulating free DNA (cfDNA) has become consolidated as an emerging biomarker and a tool for the research, diagnosis, and prognosis of solid tumors (1). Different studies have confirmed that this type of DNA contains information on specific tumor-related alterations, such as mutations, methylations, and copy number variants (CNVs) (2). The most striking advantage of LB is its ability to isolate ctDNA through a minimally invasive technique (1,3).
Publisher
Academia Nacional de Medicina (Colombia)